*senior author, #equal contribution

  1. Abad E, Sandoz J, Romero G, Urgel-Solas J, Borredat B, Kourtis S, Ortet L, Martínez C, Sdelci S, Janic A*. (2024) The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability. Journal of Experimental & Clinical Cancer Research. in press
  2. Janic A*, Abad E, Amelio I*. (2024) Decoding p53 tumor suppression: a crosstalk between genomic stability and epigenetic control? Cell Death & Differentiation. doi: 10.1038/s41418-024-01259-9
  3. Brennan MS, Brinkmann K, Romero G, Potts M, Healey G, Gangoda L, Lieschke E, Wilcox S, Strasser A*, Herold MJ*, Janic A*. (2023) Combined absence of TRP53 target genes ZMAT3, PUMA and p21 cause a high incidence of cancer in mice. Cell Death & Differentiation. doi:10.1038/s41418-023-01250-w. 
  4. Moretton A, Kourtis S, Gañez Zapater A, Calabrò C, Espinar Calvo ML, Fontaine F, Darai E, Abad Cortel E, Block S, Pascual-Reguant L, Pardo-Lorente N, Ghose R, Vander Heiden MG, Janic A, Müller AC, Loizou JI, Sdelci S. (2023) A metabolic map of the DNA damage response identifies PRDX1 in the control of nuclear ROS scavenging and aspartate availability. Mol Syst Biol. doi: 10.15252/msb.202211267.
  5. Vitale I et al., Apoptotic cell death in disease-Current understanding of the NCCD 2023. (2023) Cell Death & Differentiation. doi: 10.1038/s41418-023-01153-w. 
  6. Best SA, Vandenberg CJ, Abad E, Whitehead L, Guiu L, Ding S, Brennan MS, Strasser A, Herold MJ, Sutherland K*, Janic A*. (2020)Consequences of ZMAT3 loss in c-MYC- and mutant KRAS-driven tumorigenesis.Cell Death & Disease. doi:10.1038/s41419-020-03066-9
  7. Janic A, Valente LJ, Milla L, Wilcox S, Yang H, Tai L, Vandenberg CJ, Kueh AJ, Mizutani S, Brenan MS, Schenk RL, Lindquist LM, Papenfuss T, O’Connor L, Strasser A, Herold MJ. (2018) DNA repair processes are critical mediators for p53-mediated tumour suppression. Nature Medicine. doi:10.1038/s41591-018-0043-5.
  8. Aubrey BJ, Janic A#, Chen Y#, Chang C, Lieschke EC, Diepstraten ST, Kueh AJ, Bernardini JP, Dewson G, O'Reilly LA, Whitehead L, Voss AK, Smyth GK, Strasser A, Kelly GL. (2018) Mutant TP53 exerts a target gene-selective dominat-negative effect to drive tumour development. Genes & Development. doi. 10.1101/gad.314286.118.
  9. Aubrey BJ#, Kelly GL#, Janic A#, Herold MJ#, Strasser A*. (2017) How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Review. Cell Death and Differentiation. doi:10.1038/cdd.2017.169.
  10. Valente LJ, Grabow S, Vandenberg CJ, Strasser A*, Janic A* (2016). Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53. Oncogene. doi:10.1038/onc.2015.457.
  11. Valente LJ, Gray HD, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL, Janic A*, Strasser A*. (2013) p53 efficiently suppresses tumor development in the complete absence of its cell cycle inhibitory and pro-apoptotic effecters p21, Puma and Noxa. Cell reports. doi: 10.1016/j.celrep.2013.04.012. 
  12. Nielsen PM, Braithwaite AW, Gamell C, Haupt S, Janic A, Strasser A, Wolyniec K, Haupt Y., (2013) Stimulating p53 down-under: a report from the 1st Australian p53 Workshop. Cell Death and Differentiation. doi:10.1038/cdd.2013.2
  13. Janic A, Mendizabal L, Llamazares S, Rossell D, Gonzalez C., (2010) Ectopic expression of germline genes drives malignant brain tumor growth in Drosophila. Science. doi.10.1126/science
  14. Martinez AM, Schuettengruber B, Sakr S, Janic A, Gonzalez C, Cavalli G., (2009) Polyhomeotic has a tumor suppressor activity mediated by repression of Notch signaling. Nature Genetics. doi: 10.1038/ng.414